Disclosed herein are recombinant polypeptides derived from FBP1 and FBP2. Also disclosed herein are recombinant expression vectors and recombinant host cells for producing the aforesaid recombinant polypeptides. The recombinant polypeptides are proven to be useful and effective in producing a picornavirus with a type I internal ribosome entry site (IRES), so as to facilitate the preparation of a viral vaccine.

A method of producing plant virus-like particles includes freeze drying an aqueous solution of plant virus particles to produce a substantially RNA-free plant virus-like particles.

The disclosure provides a recombinant nucleic acid of Seneca valley virus, a recombinant vaccine strain and preparation method and use thereof, and relates to the technical field of genetic engineering. The disclosure provides the recombinant nucleic acid of Seneca valley virus, recombinant Seneca valley virus comprising the recombinant nucleic acid, recombinant Seneca valley virus encoded by the recombinant nucleic acid, recombinant Seneca valley virus vaccine strain comprising the recombinant Seneca valley virus and preparation method and use thereof. According to the disclosure, a vaccine strain characterized by high antigen production capacity, remarkably reduced pathogenicity (even having no pathogenicity to pigs), strong antibody induction activity, high immune protection rate is prepared. The vaccine strain remarkably improves the biological safety and can be used for preventing and controlling Seneca valley virus in China and the neighboring countries.

Virus particle multimers and methods of making and using such virus particle multimer are described. Virus particle multimers are constructed by preparing a plurality of asymmetrically functionalized virus particles bearing one or more functional groups and contacting the asymmetrically functionalized virus particles with a first linker molecule that reacts with the functional groups to form a virus particle multimer that includes a plurality of asymmetrically functionalized virus particles connected by the linker molecule. The asymmetrically functionalized virus particles are typically prepared by attaching the virus particles to a support surface to allow asymmetrical functionalization to be introduced.

The present disclosure relates to recombinant RNA molecules encoding an oncolytic virus. The present disclosure further relates to the encapsulation of the recombinant RNA molecules and the use of the recombinant RNA molecules and/or particles for the treatment and prevention of cancer.

A method of producing plant virus-like particles includes freeze drying an aqueous solution of plant virus particles to produce a substantially RNA-free plant virus-like particles.

Virus particle multimers and methods of making and using such virus particle multimer are described. Virus particle multimers are constructed by preparing a plurality of asymmetrically functionalized virus particles bearing one or more functional groups and contacting the asymmetrically functionalized virus particles with a first linker molecule that reacts with the functional groups to form a virus particle multimer that includes a plurality of asymmetrically functionalized virus particles connected by the linker molecule. The asymmetrically functionalized virus particles are typically prepared by attaching the virus particles to a support surface to allow asymmetrical functionalization to be introduced.

Methods for producing viruses from adherent cells are provided. The methods include releasing virus from adherent host cells grown in a bioreactor, and purifying released virus by ultrafiltration and/or diafiltration. The methods can be used to manufacture viruses, including for clinical use, at reduced cost relative to conventional virus manufacturing methods.

A method of producing plant virus-like particles includes freeze drying an aqueous solution of plant virus particles to produce a substantially RNA-free plant virus-like particles.

Disclosed herein are recombinant polypeptides derived from FBP1 and FBP2. Also disclosed herein are recombinant expression vectors and recombinant host cells for producing the aforesaid recombinant polypeptides. The recombinant polypeptides are proven to be useful and effective in producing a picornavirus with a type I internal ribosome entry site (IRES), so as to facilitate the preparation of a viral vaccine.